Industry wary of new German pricing rule

Share this article:

Germany's a tough market for drugmakers, and in two months, the country's move to disclose discounted drug prices has pharmaceutical manufacturers worried about the impact this transparency will have on their ability to raise prices in other territories.

Reuters reports that the new law, which is set to go into effect in April, is intended to force pricing to be based on discounts, not wholesale prices, because the discounted prices, which Reuters says can be around 20%, will now be out in the open. Reuters says the concern is that some countries already use Germany's pricing as a benchmark, and this new peg would mean even lower prices in even more geographies should the math go live.

Jagen Pfundner, the chairman of Germany's pharma lobby VFA, and head of Swiss drugmaker Roche's German unit, told Reuters that drugmakers may keep certain drugs off the German market to avoid a watershed of discounts, but Reuters notes this would also mean opting out of the world's third-largest drug market.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.